Next generation pneumococcal vaccines

Current Opinion in Immunology

Volumn 23, Issue 3, 2011, Pages 407-413

  Moffitt, Kristin L ^a   Malley, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ALUMINUM HYDROXIDE; BACTERIUM ANTIBODY; BINDING PROTEIN; CHOLINE BINDING PROTEIN A; CYTOLYSIN; DIPHTHERIA TOXOID CRM197; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; DISEASE MODEL; DRUG EFFICACY; DRUG TARGETING; HERD IMMUNITY; HUMAN; INFECTION RESISTANCE; NONHUMAN; PNEUMOCOCCAL INFECTION; PROTEOMICS; REVIEW; SALMONELLA TYPHI; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 79957729510     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.04.002     Document Type: Review

References (48)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., Lee E., Mulholland K., Levine O.S., Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Reingold A., Thomas A., Schaffner W., Craig A.S., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
3. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., Lexau C.A., Thomas A.R., Harrison L.H., Reingold A.L., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295:1668-1674.
4. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., Butler J.C., Rudolph K., Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792.
5. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., Farley M.M., Jorgensen J.H., Lexau C.A., Petit S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
6. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997, 94:6571-6576.
7. Lipsitch M., Whitney C.G., Zell E., Kaijalainen T., Dagan R., Malley R. Age-specific incidence of invasive pneumococcal disease by serotype: are anticapsular antibodies the primary mechanism of protection against invasive disease?. PLOS Med 2005, 2:e15.
8. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 2005, 102:4848-4853.
9. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., Kolls J.K., Srivastava A., Lundgren A., Forte S., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4:e1000159.
10. Wu H.-Y., Virolainen A., Mathews B., King J., Russell M.W., Briles D.E. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 1997, 23:127-137.
11. Hogberg L., Geli P., Ringberg H., Melander E., Lipsitch M., Ekdahl K. Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J Clin Microbiol 2007, 45:948-952.
12. Takashima K., Tateda K., Matsumoto T., Iizawa Y., Nakao M., Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997, 65:257-260.
13. Balachandran P., Brooks-Walter A., Virolainen-Julkunen A., Hollingshead S.K., Briles D.E. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 2002, 70:2526-2534.
14. Boslego J: Pneumococcal Vaccines: Progress and Challenges. In Phacilitate's 9th Annual North American Vaccine Forum January 25, 2011. Washington, DC; 2011.
15. Wizemann T.M., Heinrichs J.H., Adamou J.E., Erwin A.L., Kunsch C., Choi G.H., Barash S.C., Rosen C.A., Masure H.R., Tuomanen E., et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001, 69:1593-1598.
16. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., Dagan R., Brewah Y.A., Barren P., Lathigra R., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69:949-958.
17. Denoel P., Godfroid F., Hermand P., Verlant V., Poolman J. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides. Vaccine 2011.
18. Giefing C., Meinke A.L., Hanner M., Henics T., Bui M.D., Gelbmann D., Lundberg U., Senn B.M., Schunn M., Habel A., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008, 205:117-131.
19. Nagy E: A novel protein-based pneumococcal vaccine: From bench to the clinic. Edited by Disease tISoPaP. Tel Aviv; 2010.
20. Ochs M.M., Bartlett W., Briles D.E., Hicks B., Jurkuvenas A., Lau P., Ren B., Millar A. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog 2008, 44:204-214.
21. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., Flechtner J.B., Higgins D.E., Malley R. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9:158-165.
22. Chien Y.W., Klugman K.P., Morens D.M. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 2010, 202:1639-1648.
23. Lu Y.J., Yadav P., Clements J.D., Forte S., Srivastava A., Thompson C.M., Seid R., Look J., Alderson M., Tate A., et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 2010, 17:1005-1012.
24. Lu Y.J., Leite L., Goncalves V.M., Dias Wde O., Liberman C., Fratelli F., Alderson M., Tate A., Maisonneuve J.F., Robertson G., et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28:7468-7475.
25. Curtiss R., Xin W., Li Y., Kong W., Wanda S.Y., Gunn B., Wang S. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010, 30:255-270.
26. Wang S., Li Y., Shi H., Sun W., Roland K.L., Curtiss R. Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines. Infect Immun 2011, 79:937-949.
27. Wang S., Li Y., Shi H., Scarpellini G., Torres-Escobar A., Roland K.L., Curtiss R. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun 2010, 78:3258-3271.
28. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997, 175:839-846.
29. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., Ferguson L.M., Nahm M.H., Nabors G.S. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182:1694-1701.
30. Glover D.T., Hollingshead S.K., Briles D.E. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 2008, 76:2767-2776.
31. Lock R.A., Hansman D., Paton J.C. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 1992, 12:137-143.
32. Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., Hansman D., Paton J.C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994, 62:5683-5688.
33. Gianfaldoni C., Maccari S., Pancotto L., Rossi G., Hilleringmann M., Pansegrau W., Sinisi A., Moschioni M., Masignani V., Rappuoli R., et al. Sortase A confers protection against Streptococcus pneumoniae in mice. Infect Immun 2009, 77:2957-2961.
34. Moschioni M., Emolo C., Biagini M., Maccari S., Pansegrau W., Donati C., Hilleringmann M., Ferlenghi I., Ruggiero P., Sinisi A., et al. The two variants of the Streptococcus pneumoniae pilus 1 RrgA adhesin retain the same function and elicit cross-protection in vivo. Infect Immun 2010, 78:5033-5042.
35. Gianfaldoni C., Censini S., Hilleringmann M., Moschioni M., Facciotti C., Pansegrau W., Masignani V., Covacci A., Rappuoli R., Barocchi M.A., et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007, 75:1059-1062.
36. Lock R.A., Paton J.C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog 1988, 5:461-467.
37. Long J.P., Tong H.H., DeMaria T.F. Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model. Infect Immun 2004, 72:4309-4313.
38. Jomaa M., Terry S., Hale C., Jones C., Dougan G., Brown J. Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae. Vaccine 2006, 24:5133-5139.
39. Brown J.S., Gilliland S.M., Holden D.W. A Streptococcus pneumoniae pathogenicity island encoding an ABC transporter involved in iron uptake and virulence. Mol Microbiol 2001, 40:572-585.
40. Talkington D.F., Brown B.G., Tharpe J.A., Koenig A., Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 1996, 21:17-22.
41. Whaley M.J., Sampson J.S., Johnson S.E., Rajam G., Stinson-Parks A., Holder P., Mauro E., Romero-Steiner S., Carlone G.M., Ades E.W. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine 2010, 28:3071-3075.
42. Shah P., Briles D.E., King J., Hale Y., Swiatlo E. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae. Exp Biol Med (Maywood) 2009, 234:403-409.
43. Shah P., Swiatlo E. Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun 2006, 74:5888-5892.
44. Cao J., Chen T., Li D., Wong C.K., Chen D., Xu W., Zhang X., Lam C.W., Yin Y. Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice. Microb Infect 2008, 10:1536-1542.
45. Cao J., Gong Y., Li D., Yin N., Chen T., Xu W., Zhang X., Yin Y. CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. Vaccine 2009, 27:2838-2844.
46. Godfroid F., Hermand P., Verlant V., Denoel P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79:238-245.
47. Green B.A., Zhang Y., Masi A.W., Barniak V., Wetherell M., Smith R.P., Reddy M.S., Zhu D. PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 2005, 73:981-989.
48. Medina M., Villena J., Vintini E., Hebert E.M., Raya R., Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 2008, 76:2696-2705.